Improvement of Quality of Life with Shenfu Injection (参附注射液) in Non Small Cell Lung Cancer Patients Treated with Gemcitabine plus Cisplatin Regimen

Objective： To observe the effect of Shenfu injection （参附注射液, SFI） in treating non small cell lung cancer （NSCLC） patients on quality of life with gemcitabine （GEM） plus cisplatin （GP） regimen. Methods： Thirty-four patients were ready to receive GP regimen chemotherapy for treating NSCLC disease, according to lot-drawing, they were divided into SFI pre-treatment group （18 cases） and SFI post-treatment group （ 16 cases）. SFI pre-treatment group： During the first treatment course, chemotherapy was begun with SFI 60 ml, intravenous dripping on the 3rd day, once daily, consecutively for 10 days; on the 1st day, GP regimen （GEM 1250 mg/m^2 , intravenous dripping, on the 1st and 8th day; cisplatin 70 mg/m^2 on the 2nd day; 21 days as one cycle） was carried out; in the second treatment course GP regimen was merely given to serve as the self-control. SFI post-treatment group： the medicament sequence order was reversed from that of pre-treatment group. Using dual international quality of life （QOL） scores, the effect of SFI on the patients＂ QOL was observed through randomized self pre- and post- crossover control. Results： The QOL in the 34 patients after being treated by SFI in combination with GP chemotherapy regimen in one group, and GP chemotherapy regimen alone in the other, was improved in different degrees, with significant difference （P〈0.01）; comparision of SFI combined with GP chemotherapy regimen with GP chemotherapy alone showed that QOL in patients was significantly different （P〈0.01）. Conclusion： SFI could improve QOL in patients with NSCLC who were treated with GP regimen.

Effect of shenfu injection on gastrointestinal microcirculation in rabbits after myocardial ischemia-reperfusion injury

AIM： To investigate the effect of shenfu injection on gastrointestinal microcirculation after myocardial ischemic-reperfusion （IR） injury in rabbits and probe into the mechanism. METHODS： Forty healthy flap-eared white rabbits were randomly divided into 4 groups： IR injury control group （group Ⅰ ）, shenfu injection 5 mL/kg per h group （group Ⅱ）, shenfu injection 10 mL/kg per h group （group Ⅲ） and shenfu injection 20 mL/kg per h group （group Ⅳ）. The four groups were treated with Lactated Ringer＇s solution, shenfu injection 5, 10, and 20 mL/ kg per h were infused intravenously 30 min before experiment respectively. The values of hemodynamics [mean arterial pressure （MAP）, heart rate （HR）, gastric intramucosal partial pressure of carbon dioxide （PCO2）, blood gas analysis and pH] were measured and compared with those before myocardial ischemia, 60 min after myocardial ischemia and 60, 90, and 180 rain after reperfusion. RESULTS： The MAP, HR and gastric intramucosal pH were （70.50 ± 4.50） kPa, （165 ± 14） beats per rain, 7.032 ± 0.024 in group Ⅰ 60 min after myocardial ischemia, which were significantly decreased compared with those before myocardial ischemia （88.50 ± 9.75 kPa, 217 ± 18 beats per rain, 7.112 ± 0.035, P 〈 0.05）. The MAP, HR and gastric intramucosal pH were significantly decreased in group Ⅰ 60, 90, and 180 min after reperfusion （61.50 ± 5.25 kPa, 133 ± 31 beats per rain, 6.997 ± 0.025） compared with those before reperfusion respectively （P 〈 0.05）, whereas the values were insignificantly different in groups Ⅱ, Ⅲ or Ⅳ after reperfusion, compared with those before reperfusion, and there were no significant differences between groups Ⅱ, Ⅲ, and Ⅳ after reperfusion. CONCLUSION： Pre-infusion of shenfu injection has a protective effect on gastrointestinal microcirculation after myocardial IR injury in rabbits, in a dose independent manner.

Effect of Shenfu injection on ischemia-reperfusion injury of rat liver graft

BACKGROUND: It is reported that Shenfu injection (an injection prepared from traditional Chinese medicines red ginseng and aconite root) can decrease the extent of ischemia-reperfusion injury to many organs, such as the heart and kidney. We therefore investigated the effect of Shenfu injection on ischemia-reperfusion injury of rat liver graft and its mechanism. METHODS: Male Sprague Dawley (SD) rats were used as a model for isogeneic orthotopic liver transplantation. Sixty rats were randomly devided into two groups (30 in each group). The recipient was given intravenous Shenfu injection immediately before the removal of the liver in the Shenfu group and normal saline of the same volume in the control group. At 3, 6 and 24 hours after the reperfusion, blood and hepatic tissue were taken for examination. RESULTS: The levels of superoxide dismutase (SOD) and nitric oxide (NO) increased more significantly in the Shenfu group than in the control group (P <0.05). The levels of serum liver enzymes, hyaluronic acid (HA), malondialde-hyde (MDA), tumor necrosis factor-alpha(TNF-α), inter-leukin-1 (IL-1), endothelin -1 (ET-1) and liver cell apopto-sis index were lower in the Shenfu group than in the control group (P <0. 05). Microscopic examination revealed that the morphological changes of hepatic tissue were more severe in the control group than in the Shenfu group. CONCLUSIONS: Shenfu injection has protective effect on ischemia-reperfusion injury of rat liver graft. It inhibits the production of oxygen free radical and the activation of Kupffer cells, decreases apoptosis of liver cell, and improves microcirculation.

Effect of Shenfu injection on microcirculation effect index in early-and middle-stage of cardiogenic shock rats

OBJECTIVE Shenfu injection(SFI)is an effective treatment of cardiogenic shock,the pathology of the central link was microcirculation disturbance.However,whether the microcirculation status of the early-and mid-stage of cardiogenic shock has any difference is unclear.This study aimed to observe the effect of SFI on the microcirculatory disturbance in mesentery for early-and mid-stage of cardiogenic shock rat.METHODS The early-and mid-stage model of cardiogenic shock was established by ligating the ending or root of left anterior descending coronary arteries(LADCA).The rats were randomly divided into 9 groups,ie control group,early-stage model group,mid-stage model group,3 early medicated groups and 3 mid medicated groups(the dosage was 1,3.33,10 mL·kg^(-1) SFI for cardiogenic shock rats of early-and mid-stage,respectively).Parameters in mesenteric microcirculation,such as velocity of RBCs in venules,diameters of venules,the count of leukocyte adhesion and vascular permeability which calculated by FITC-dextran leakage were observed through an GeneandiM2 inverted intravital microscope and high-speed video camera system.RESULTS The cardiogenic shock induced by ligating the LADCA resulted in a number of responses in microcirculation,including a significant increase in the counts of adhesive leukocytes,narrowing of the vascular diameter,decrease in the velocity of RBCs and dextran efflux.All of the above parameters for early-stage cardiogenic shock rats were attenuated by the treatment with SFI,especially the dosage of 10 mL·kg^(-1).While SFI had no apparent time-effect on the vascular diameter and vascular permeability in mesentery for mid-stage cardiogenic shock rats.CONCLUSION The microcirculation status of the early-and mid-stage of cardiogenic shock rats were quite different.The efficacy of early treatment with SFI was more obvious than the mid administration,which could provide experimental and theoretical basis for the patients with cardiogenic shock in an earlier time.

Shenfu injection plus vinorelbine for elderly patients with non-small cell lung cancer in promoting the quality of life: a randomized controlled clinical trial

Objective： The present study aimed to investigate the efficacy of Shenfu injection plus vinorelbine on the promotion of the quality of life （QOL） in elderly non-small cell lung cancer （NSCLC） patients. Methods： A randomized single blind trial method was used. Forty-six patients with stage IIIB-IV of HSCLC were randomly divided into experimental group and control group. In the experimental group, the patients were treated with 50 mL Shenfu injection from day 1 to 14, plus vinorelbine （NVB） 25 mg/m^2 on day 1 and 8. In the control group, the patients were only treated with NVB 25 mg/m^2 on day 1 and 8. After two cycle＇s of treatment, QOL, efficacy and toxicity were observed. Results： The QOL was enhanced in both experimental group and control group. However, the difference of KPS after treatment in the experimental group was markedly higher than in the control group （14 ± 10 vs. 8 ± 10, t = 2.116, P = 0.04）, improvement rate of QOL was better than in the control group （76.2% vs. 45.0%, χ^2 = 4.188, P = 0.041）, treatment related toxicity in the experimental group was also markedly lower than in the control group （χ^2 = 3.866, P = 0.049）, but the difference of efficacy between the two groups was not significant （14.3% vs. 15.0%, χ^2 = 0.161, P = 0.688）. Conclusion： Shenfu injection plus vinorelbine can enhance QOL in elderly NSCLC patients.

Therapeutic Effect of Shenfu Injection (参附注射液) on Secondary Aplastic Anemia of Tumor Patients after Chemotherapy

Objective: To explore the effect of Shenfu Injection (参府注射液, SFI) on the secondary aplastic anemia (AA) of tumor patients after chemotherapy (CT). Methods: The 15 cases of SFI treated group, 10 cases of control group, 25 cases of SFI + granulocyte-macrophage colony stimulating factor (GM-CSF) treated group and the group of 23 GM-CSF-treated tumor cases of secondary AA after CT were compared, with their increasing rate and the rebound speed of neutrophil, platelet, bone marrow nucleated RBC, granulocyte, and megakaryocyte all being investigated. Results: The increasing rate and rebound speed of granulocyte, platelet, and the increasing rate of bone marrow nucleated RBC, granulocyte, megakaryocyte were obviously higher than those of the control, and the clinical manifestations were also obviously improved. The increasing rate of platelet, bone marrow nucleated RBC, megakaryocyte of the SFI + GM-CSF group were higher than those of the group which used GM-CSF alone, while the increasing rate of granulocyte in blood and bone marrow in both groups was similar. Conclusion: Significant efficacy was shown in SFI for the treatment of secondary AA of tumor patients after CT.

Protective Effect of Shenfu Injection on Rats with Chronic Heart Failure Induced by Doxorubicin

[Objectives] To determine the protective effect of Shenfu injection( SFI) on chronic heart failure( CHF) in rats induced by doxorubicin. [Methods] CHF was induced by doxorubicin via intraperitoneal injection in rats. The cardiac function parameters,the heart index,the serum brain natriuretic peptide( BNP) level and cardiac histopathology were measured 4 weeks after Shenfu injection treatment. [Results]Shenfu injection remarkably improved the heart index and cardiac histopathology,increased the heart rate( HR),left ventricular systolic pressure( LVSP),maximum rising rate of left ventricular pressure( + dp/dtmax) and dropping rate of left ventricular pressure(-dp/dtmax),reduced the left ventricular end-diastolic pressure( LVEDP) and serum BNP level of rats with CHF induced by doxorubicin. [Conclusions]Shenfu injection exerts protective effect on CHF induced by doxorubicin.

Exploration on the Effect and Mechanism of Shenfu Injection (参附注射液) on Resuscitation from General Anesthesia

Objective: To investigate the effect and the mechanism of Shenfu injection (SFI, ) on the resuscitation from general anesthesia . Methods: Forty patients who received selective abdominal surgery with general anesthesia for 3-4 hrs and ASA grade Ⅰ-Ⅱ were divided into two groups, the trial group and the control group, 20 patients in each group. After being sent into the postanesthesia care unit (PACU), the trial group was treated with intravenous dripping of SFI 1.0 ml/kg and the control group was treated with intravenous dripping of equal volume of normal saline. All patients were observed in double blindly manner, the self ventilation recovery time, extubation time, the time of leaving PACU and their Glasgow coma scale (GCS) were recorded and compared. 2 ml of peripheral venous blood were taken to determine the plasma β-endorphin (β-EP) content at the time points of before (T1), 5min (T2), 15min (T3) and 30 min (T4) after dripping. Results: The self ventilation recovery time, extubation time and time of leaving PACU in the trial group were all shorter than those in the control group (P<0 01), the GCS in the trial group was better than that in the control group (P<0 01). The plasma content of β-EP raised gradually along the recovering of patients consciousness, as compared with the content before dripping (T1), it showed insignificant difference at time point T2 but significant difference at T3 and T4, comparison at the corres ponding time point showed that the content at T1 and T2 were similar in the two groups (P>0 05), but at T3 and T4, the content was higher in the trial group than that in the control group respectively (P<0 01). There was insignificant difference between T1 and before treatment ( P>0 05), but significant difference was found when compared T3, T4 and before treatment (P<0 01).Conclusion: SFI could accelerate the resuscitation after general anesthesia, the mechanism may be related with its action in raising plasma β-EP level.

Systematic Evaluation and Meta-Analysis of the Efficacy and Safety of Shenfu Injection in the Treatment of Septic Cardiomyopathy

Objective:To evaluate the efficacy and safety of Shenfu injection in the treatment of septic cardiomyopathy.Methods:Literatures on Shenfu injection for the treatment of sepsis published from the establishment of each database to December 31,2020,were searched by computer;Cochrane risk-of-bias tool was used for evaluating the quality of literatures,and Review Manager 5.4 software was used for meta-analysis.Results:Twenty random controlled trials(RCTs)were included,with a total of 1,179 patients;the meta-analysis showed that the routine treatment of Western medicine combined with Shenfu injection can reduce the 28-day mortality,the length of hospital stay,cardiac troponin I(cTnI),and N-terminal pro-brain natriuretic peptide(NT-proBNP)as well as improve the left ventricular ejection fraction(LVEF)with low incidence of adverse reactions.Conclusion:Western medicine combined with Shenfu injection can further reduce myocardial injury in patients with sepsis and improve cardiac function as well as the prognosis of patients with septic cardiomyopathy.

Meta-analysis of the Effect of Shenfu Injection on Immune Function in Patients with Sepsis

Objective:To systematically evaluate the effects of Shenfu Injection on immune function of sepsis patients by meta-analysis.Methods:The randomized controlled trials of Shenfu Injection in the treatment of sepsis published from 2000 to February 2021 were searched in CNKI,WanFang database and VIP database.The control group was treated with routine treatment;The experimental group was treated with Shenfu Injection on the basis of routine treatment.The included literature was evaluated by Cochrane bias risk evaluation table,and Shenfu Injection was used to treat patients with sepsis with RevMan 5.3 software.The results of meta-analysis were as reported.Conclusion:However,due to the limitation of the quality and quantity of the included research,multi center,large sample volume and high-quality RCT are still needed to verify the research results.

参附注射液通过NgR1/Lingo-1/p75NTR复合物及RhoA/ROCKⅡ信号通路减轻心肺复苏脑损伤机制的研究

目的观察参附注射液对心脏骤停后脑缺血再灌注损伤大鼠的神经保护作用,研究其是否通过调控NgR1/RhoA/ROCKⅡ信号通路及其上游因子Nogo受体相互作用蛋白1(Lingo-1)和p75神经营养因子受体(p75NTR),减轻脑损伤并促进神经轴突再生。方法制备心脏骤停/心肺复苏大鼠模型,将大鼠分为模型组、参附组、拮抗剂组及参拮组。通过ELISA检测各组脑组织中NgR1、p75NTR、Lingo-1、RhoA和RockⅡ的表达水平,并通过HE染色观察脑组织损伤情况。结果ELISA结果显示,心脏骤停后大鼠脑皮层中,模型组的各指标表达在特定时间点显著升高,尤其在3 d时NgR1、p75NTR、RhoA和ROCKⅡ达到峰值,显著高于空白组(P<0.01);参附组、拮抗剂组及参拮组的各指标表达水平均显著低于模型组(P<0.01),其中参拮组在所有时间点均表现出较低的NgR1、p75NTR、Lingo-1、RhoA及ROCKⅡ水平,尤其在3 d和7 d的ROCKⅡ和RhoA表达方面,显著低于模型组(P<0.01),RhoA在7 d时显著低于空白组(P<0.01)。HE染色结果表明,参附组和参拮组在各时间点的脑组织结构恢复效果优于模型组,细胞排列改善,水肿减轻。结论参附注射液通过调控NgR1/RhoA/ROCKⅡ信号通路及其上游因子,减轻了心脏骤停后脑缺血再灌注损伤,促进了神经轴突再生与功能恢复。

参附汤治疗重症脑缺血作用机制的网络药理学和分子对接研究

目的基于网络药理学及分子对接技术,分析参附汤治疗重症缺血性脑卒中(SIS)的作用机制。方法通过TCMSP数据库,筛选人参、附子的主要活性成分及作用靶点;通过TTD、PharmGKB、OMIM、DrugBank、GeneCards 5个数据库获取SIS的相关靶点;将得到的药物关键活性成分与疾病基因输入R语言中获得交集基因,并在UniProt数据库进行标准化命名;利用STRING数据库构建PPI网络,借助Cytoscape-CytoNCA进一步获得参附汤治疗SIS的关键靶点;利用R语言中的Bioconductor生物学数据包进行GO、KEGG分析,并运用Cytoscape3.8.2软件构建“药物-活性成分-靶基因-通路”调控网络;利用AutoDock Vina软件进行分子对接验证。结果参附汤治疗SIS的核心活性成分包括人参皂苷Rh2、山柰酚、双蒽胺、黄酮A、β-谷甾醇等;核心靶点包括Akt1、IL-1β、PTGS2、CASP3等;核心通路包括钙信号通路、TNF信号通路、流体剪切应力与动脉粥样硬化、Toll样受体信号通路等;分子对接表明主要活性成分可与核心靶点紧密结合。结论参附汤中的主要活性成分作用于多个SIS相关靶点,可能通过调节炎症反应、细胞凋亡和氧化应激等生物过程,发挥抑制炎症、抗氧化和保护脑部神经元的作用,从而治疗SIS。

参附注射液联合贝那普利治疗高血压并发急性左心衰竭的临床效果

目的探究参附注射液联合贝那普利治疗高血压(HTN)并发急性左心衰竭(ALVF)效果。方法选择2021年4月至2023年4月期间商丘市第四人民医院收治的94例HTN并发ALVF患者进行研究,应用随机数表法将其分为对照组(贝那普利)及观察组(贝那普利联合参附注射液)各47例,对比两组血压水平[舒张压(DBP)、收缩压(SBP)、脉压(PP)]、临床疗效、心功能[左室射血分数(LVEF)、左心室舒张末径(LVDD)、左心室收缩末径(LVSD)]、心肌损伤标志物[心肌肌钙蛋白(cTnI)、肌酸激酶同工酶(CK-MB)、N末端B型利钠肽原(NT-proBNP)]、不良反应发生率。结果治疗后,两组DBP、SBP、PP水平均降低,且观察组低于对照组,差异有统计学意义(P<0.05)。观察组治疗有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组LVEF水平升高,LVDD、LVSD水平降低,且观察组LVEF水平高于对照组、LVDD、LVSD水平低于对照组,差异有统计学意义(P<0.05)。治疗后,两组cTnI、CK-MB、NT-proBNP水平均降低,且观察组低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论高血压并发急性左心衰患者采用参附注射液联合贝那普利治疗,疗效显著,可改善心功能,减轻心肌损伤,且不会额外增加不良反应。

Cardioprotection of Shenfu preparata on cardiac myocytes through cytochrome P450 2J3

To evaluate whether Shenfu injection （SFI） protects against cardiac myocyte injury induced by Fupian injection （FPI） in vitro. METHODS： H9c2 cells were separately treated with FPI, Renshen injection （RSI） and SFI. Cell viability, lactate dehydrogenase （LDH） release, spontaneous beating rate of primative cardical cells, caspase-3/7 activity, cell apoptosis, and cytochrome P450 2J3 （CYP2J3） mRNA expression were analyzed. RESULTS： The viability of H9c2 cells treated with SFI （37 and 75 mg/mL） was significantly higher than that of H9c2 cells treated with FPI （25 and 50 mg/mL） （P〈0.05, P〈0.01, respectively）. LDH activity of H9c2 cells treated with SFI （75 mg/mL） was significantly decreased （P〈0.01） compared with that of H9c2 cells treated with FPI （50 mg/mL）. SFI （150 mg/mL） significantly attenuated FPI （100 mg/mL）-induced spontaneous beating rate decrease in primary myocardial cells after 4-hour treatment. Compared with FPI （12 and 25 mg/mL）, SFI （18 and 37 mg/mL） treatment could effectively reverse the change of caspase-3/7 activity （P〈0.01 and P〈0.01, respectively）. Compared with FPI （6 and 25 mg/mL）, apoptotic cells decreased significantly （P〈0.05, P〈0.01, respectively） when H9c2 cells were incubated with SFI （9 and 37 mg/mL）. The expression of CYP2J3 mRNA was down-regulated by FPI, while RSI and SFI could up-regulate the expression of CYP2J3 （P〈0.01）, which suggested the potential mechanism of protection of RSI against cardiac myocyte damage induced by FPI treatment. CONCLUSION： These observations indicate that SFI has the potential to exert cardioprotective effects against FPI toxicity. The effect was possibly correlated with the activation of CYP2J3.

重组人B型钠尿肽联合参附注射液治疗急性心力衰竭的疗效及对sNEP、miR-181b、Cys-C的影响

目的探讨重组人B型钠尿肽(NPPB)联合参附注射液治疗急性心力衰竭对血清可溶性脑啡肽酶(sNEP)、微小RNA-181b(miR-181b)、胱抑素C(Cys-C)水平的影响。方法选取濮阳市中医医院2018年1月至2020年1月收治的82例急性心力衰竭患者,随机分为对照组和观察组,各41例。对照组采用NPPB治疗,观察组加用参附注射液治疗,两组均治疗14 d。比较两组治疗前后体征变化、心功能、血管内皮功能、sNEP、miR-181b、Cys-C水平、不良心血管事件。结果治疗后,两组心率、呼吸频率均降低,且观察组低于对照组,两组血氧饱和度均升高,且观察组高于对照组,差异有统计学意义(P<0.05)。治疗后,两组左心室射血分数(LVEF)水平均升高,且观察组高于对照组,左心室收缩末期容积(LVESV)、左心室舒张末期容积(LVEDV)水平均降低,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗后,两组一氧化氮水平均升高,且观察组高于对照组,内皮素-1水平均降低,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗后,两组血清sNEP、Cys-C水平均降低,且观察组低于对照组,两组miR-181b均升高,且观察组高于对照组,差异有统计学意义(P<0.05)。观察组不良心血管事件发生率低于对照组,差异有统计学意义(P<0.05)。结论NPPB联合参附注射液可有效稳定急性心力衰竭患者生命体征,改善心功能和血管内皮功能,提高miR-181b水平,降低血清sNEP、Cys-C水平,疗效确切,且安全性较高。

参附注射液联合辅酶Q10治疗急性一氧化碳中毒并发心肌损伤的临床研究

目的:探讨参附注射液联合辅酶Q10治疗急性一氧化碳中毒(ACOP)并发心肌损伤的临床疗效,并观察其对病人超声心动图指标和血清心肌损伤标志物、肿瘤坏死因子-α(TNF-α)、总抗氧化能力(T-AOC)、诱导型一氧化氮合酶(iNOS)水平的影响。方法:选取2020年1月—2023年1月我院收治的116例ACOP并发心肌损伤病人,按随机数字表法分为观察组和对照组,每组58例。观察组采用参附注射液联合辅酶Q10氯化钠注射液治疗,对照组单独采用辅酶Q10氯化钠注射液治疗,连续治疗10 d后观察两组临床疗效。比较两组治疗前后超声心动图指标[左室舒张末期内径(LVEDD)、左室射血分数(LVEF)、二尖瓣舒张早期血流峰速度(E)与二尖瓣环舒张早期运动峰速度(e')比值(E/e')]、血清心肌损伤标志物[心肌肌钙蛋白I(cTnI)、肌酸激酶同工酶(CK-MB)、心肌型脂肪酸结合蛋白(H-FABP)、N末端B型利钠肽原(NT-proBNP)]及TNF-α、T-AOC、iNOS水平。统计两组不良反应情况。结果:观察组总有效率为93.10%(54/58),高于对照组的77.59%(45/58),差异有统计学意义(P<0.05)。治疗后,两组LVEDD、E/e'及血清cTnI、CK-MB、H-FABP、NT-proBNP、TNF-α、iNOS水平均较治疗前降低,LVEF和血清T-AOC水平较治疗前增加,且观察组优于对照组,差异均有统计学意义(P<0.05)。两组不良反应均少而轻微。结论:参附注射液联合辅酶Q10治疗ACOP并发心肌损伤可调节病人血清心肌损伤标志物及TNF-α、T-AOC、iNOS水平,改善心功能,提高临床疗效。

Flotation characteristics of Shenfu coal macerals

The flotation characteristics of Shenfu coal macerals was researched. Taking flotation recovery and enrichment of macerals as the evaluation objects, the influence of the agent dosage, pulp concentration, impeller speed and aeration rate on the separating effect was investigated. And the optimum process conditions of flotation were confirmed. The results show that the agent dosage, pulp concentration, impeller speed and aeration rate have a significant impact on flotation recovery and en- richment of macerals. The float recovery was 73.28% and enrichment ratio of vitrinite was 83.89% when CTAB dosage of 1.0 kg/t, pulp concentration of 100 g/L, impeller speed of 1 700 r/min and aeration rate of 0.25 m3/（m2·min） were used. The tailings yield was 60.30% and enrichment ratio of inertinite was 61.44% when CTAB dosage of 0.5 kg/t, pulp concentration of 100 g/L, impeller speed of I 700 r/min and aeration rate of 0.20 m3/（m2·min） were used.

Network pharmacological study on the mechanism of shenfu decoction in the treatment of cardiotoxicity by doxorubicin

Objective:Doxorubicin is an efficient anthracycline drug for the treatment of tumor,however,its cardiotoxicity restricts the clinical application.Shenfu decoction has good clinical effect,but the pharmacological mechanism is not fully clarified.Method:The active components and potential targets of shenfu decoction were screened by TCMSP database,disease targets of doxorubicin-induced cardiotoxicity were collected by Genecards and OMIM database,and the network diagram of"drug-components-target-disease"was constructed by Cytoscape software.PPI network was constructed by STRING database.The target of action of the drug and the disease gene were mapped for GO and KEGG signal pathway analysis.Results:The study found that there are 52 main effective components of shenfu decoction,and 76 genes are involved in the potential therapeutic targets,among which 24 genes are potential targets of shenfu decoction in the treatment of doxorubicin-induced cardiotoxicity.The protein interaction network suggested that BCL2、BAX、CASP9、CASP3、MAPK8 may be the core target.GO enrichment analysis showed 52 cellular biological processes,and enrichment analysis of KEGG pathway revealed 99 involved signaling pathways,including TNF,apoptosis signaling pathways,etc.Conclusion:In this study,the network of"drug-components-target-disease"was constructed through network pharmacology,and it was found that the mechanism of"shenfu decoction"in the treatment of doxorubicin-induced cardiotoxicity involves multiple targets and pathways,which is conducive to guiding clinical medication.

Mechanism of Shenfu Decoction in the treatment of critically ill patients with Coronavirus Disease 2019 (COVID-19) based on network pharmacology

Objective:The purpose of this thesis is to explore the mechanism of ShenFu Decoction in the treatment of critically ill patients with COVID-19 based on network pharmacology.Methods:The primary active ingredients and potential targets of ShenFu Decoction were searched from the TCMSP database.The targets of COVID-19 were obtained by searching the GeneCards and OMIM databases.A ShenFu Decoction-compound-target-COVID19 network and a protein-protein interaction(PPI)network were respectively constructed through the Cytoscape 3.5.1 software and the STRING database.Gene Ontology(GO)function enrichment and Kyoto Encyclopedia of Genes and Genomes(KEGG)pathway analysis were performed via Bioconductor bioinformatics software package and R programming language.Results:ShenFu Decoction contains 255 compounds and 94 potential targets.43 primary active ingredients were searched from the TCMSP database with oral bioavailability(OB)≥30%and drug-likeness(DL)≥0.18 as the retrieval condition.Numbers of targets of COVID-19 were 352 by searching the GeneCards and the OMIM databases.16 key targets were acquired by intersecting the targets of drug with the targets of disease.There were 49 GO terms and 102 pathways after analyzing GO and KEGG.Conclusion:Kaempferol,ginsenoside rh2,beta-sitosterol,Stigmasterol and Deoxy andrographolide might be the main active ingredients which may cause the inhibition of the SARS-CoV-23CL hydrolase activity and regulate ACE2.As a result,the antiviral effect,immunoregulation,targeting cytokine storm of SFD may play an important role in the treatment of critically ill patients with COVID-19 through regulating multiple signaling pathways such as AGE-RAGE signaling pathway in diabetic complications,IL-17 signaling pathway,C-type lectin receptor signaling pathway,HIF-1 signaling pathway.

神府区块深部煤层气高效开发技术研究

【目的】深部煤层气是保障国家油气安全、实现碳达峰碳中和目标的重要接替资源之一,具有广阔的开发前景。但在不同地质条件下,深部煤层气开发技术的通用性较差,在某些区块成功应用的技术不能直接推广到其他区块。目前,新区块前期勘探开发时井型、井网部署还存在一定的盲目性。因此,需要研发针对神府区块深部煤层气高效开发的储层工程改造适配性技术。【方法】首先,以鄂尔多斯盆地神府区块79口生产井实际数据为基础,从产能、经济性2个方面对直井和水平井两种井型的开发效果进行比较;其次,以神府地区深部煤层地质条件为输入参数,对深部煤层水平井的合理井长进行模拟分析;最后,通过地质气藏、钻完井、工程和经济评价等多专业结合,以单位面积经济效益为优化目标,得出神府区块深部煤层气高效开发的储层工程改造具体工艺参数。【结果和结论】结果表明:神府区块深部煤层气高效开发的适合井型为水平井;可实现效益最大化时的水平井长度范围为800~1500 m;开发的最优井距为300 m、簇间距为15~20 m、半缝长为120 m,对应的压裂总液量应为(1.8~2.4)万m^(3),总砂量(0.25~0.35)万m^(3)。在上述研究的基础上,以“段内多簇+缩短簇间距+高排量大规模注入+变黏滑溜水造缝携砂+高强度加砂+全尺度裂缝支撑+等孔径限流射孔+造复杂缝网”为核心,建立了一套适合神府区块深部煤层储层改造工艺,实现了现阶段神府区块深部煤层气的高效开发,为现阶段国内其他盆地深部煤层气资源开发提供借鉴。